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ARTICLE OPEN
Reducing the use of inhaled corticosteroids in mild-moderate
COPD: an observational study in east London
James N. Cole 1✉, Rohini A. Mathur1 and Sally A. Hull 1
Inhaled corticosteroids (ICS) are often prescribed for worsening breathlessness, exacerbation frequency or lung function in chronic
obstructive pulmonary disease (COPD). In mild-moderate disease and infrequent exacerbations, treatment risks may outweigh
benefits and ICS may be withdrawn safely under supervision. A systematic ICS deprescribing programme for patients with mild-
moderate COPD was introduced in an east London Clinical Commissioning Group (CCG) in April 2017. Primary care patient record
analysis found that prescribing fell from 34.9% (n= 701) in the 18 months pre-intervention to 26.9% (n= 538) by the second year of
implementation, decreasing 0.84% per quarter post intervention (p= 0.006, linear regression). The relative decrease was greater
than the comparison CCG (23.0% vs. 9.9%). Only South Asian ethnicity was associated with increased cessation (odds ratio 1.48,
confidence interval (CI) 1.09–2.01), p= 0.013, logistic regression). Patient outcome data were not collected. A primary care-led
programme comprising local education, financial incentivisation and consultant support led to a significant decrease in ICS
prescribing.
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INTRODUCTION
Inhaled corticosteroids (ICS) have been used extensively in the
management of chronic obstructive pulmonary disease (COPD)
over the past 40 years, derived originally from their use in asthma.
The use of ICS in milder COPD has become increasingly
controversial. Randomised controlled trials (RCTs) have demon-
strated that ICS can reduce the frequency of exacerbation,
preserve lung function and slow the decline in quality of life,
but are also associated with higher prevalence of pneumonia, oral
candidiasis and voice hoarseness1. Other risks such as reduced
bone density, cataract and adrenal suppression have also been
postulated2,3.
The benefits of ICS are greatest in severe disease, where forced
expiratory volume in one second (FEV1) is <50% predicted, or
exacerbations are frequent (two or more per year). Others who are
likely to benefit include patients with a coexisting diagnosis of
asthma (asthma–COPD overlap syndrome), a history of atopy or
high blood eosinophils4. Those patients with mild-to-moderate
airflow obstruction on spirometry and infrequent exacerbations
may experience greater risks than benefits.
For over a decade, international COPD guidelines from the
Global Initiative for Chronic Obstructive Lung Disease (GOLD) have
advocated a risk stratification approach to inform ICS therapy
(https://goldcopd.org/gold-reports). Although subsequent ver-
sions have moved away from using spirometry to guide
pharmacological treatment, guidance at the inception of the
project (2016) reserved ICS for more severe cases based on
spirometry and exacerbation rate. GOLD advised that manage-
ment of mild-moderate cases (predicted FEV1 > 50%, with fewer
than two COPD exacerbations and no COPD-related hospital
admissions in the preceding year) should focus on adequate
bronchodilator therapy with long-acting β-agonist (LABA) and
long-acting muscarinic antagonist (LAMA) inhalers, alongside
influenza vaccination, smoking cessation and pulmonary rehabi-
litation. In contrast, UK guidance at the time from the National
Institute for Health and Care Excellence (NICE, 2010 guidance)
promoted the use of ICS based on symptomatology regardless of
spirometry or exacerbation rate (https://www.nice.org.uk/
guidance). Since its updated guidance in 2018, NICE now primarily
reserves ICS for patients who have features of asthma, frequent
exacerbations or features suggesting steroid responsiveness.
However, it does promote ICS for patients who remain sympto-
matic despite optimal bronchodilator therapy.
ICS continue to be prescribed in mild-to-moderate COPD
despite the adverse risk–benefit profile; however, prescribing
rates have started to decline over the past 10 years5,6.
Deprescribing of inappropriate ICS has attracted increasing
attention over recent years. A growing number of RCTs7–12
and real-world studies13,14 have explored the effects of ICS
withdrawal on breathlessness, quality of life, medication use,
lung function and exacerbation rates. Most of these have
studied heterogeneous patient groups across the spectrum of
COPD severity. Systematic reviews have demonstrated small
deteriorations in quality of life, lung function and exacerba-
tion frequency, but not to a statistically or clinically significant
degree15–17. Studies examining ICS withdrawal in the mild-
moderate group (predicted FEV > 50%) showed no deteriora-
tion in these variables provided bronchodilator therapy was
maintained12,13.
At the start of this project, there was no internationally agreed
process for ICS withdrawal, although approaches using risk
stratification based on predicted FEV1 and infrequent exacerba-
tion rates have been suggested18,19. ICS withdrawal has been
shown to be acceptable to patients in this low-risk group given
adequate explanation20.
Systematic programmes to achieve ICS reduction have been
undertaken in other parts of the United Kingdom, overseen by
respiratory consultants running virtual clinics in general practice21.
The aim of this study is to evaluate a quality improvement
programme to reduce ICS prescribing in primary care in east
London. Specific objectives include:
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(a) Comparing aggregate practice rates of ICS prescribing pre-
and post intervention among individuals with mild-
moderate COPD.
(b) Using an embedded case–control study to identify indivi-
dual level predictors of ICS cessation within the mild-
moderate COPD population.
(c) Estimating the prescribing cost savings associated with the
programme.
RESULTS
At the start of the pre-intervention period in December 2015,
there were 3918 patients on COPD GP practice registers in Tower
Hamlets from a total registered population of 309,054 (1.3%), and
3392 patients on COPD registers in City and Hackney from a
registered population of 402,087 (0.8%). Excluding those with a
historical asthma diagnosis and all those with a predicted FEV1 of
50% or below on their most recent spirometry left a study
population of 2009 individuals in Tower Hamlets and 1487
individuals in City and Hackney (see flow chart: Supplementary
Fig. 1).
Within the mild-moderate COPD intervention cohort, at base-
line 87.0% (n= 1748) had a FEV1/forced vital capacity (FVC) ratio
< 0.7; 11.9% (n= 240) had a FEV1/FVC ratio ≥ 0.7; 1.0% (n= 21)
had no FEV1/FVC recorded in the GP record.
In the first pre-intervention quarter, among those people with
mild-moderate COPD, 701 (34.9%) individuals in Tower Hamlets
and 493 (33.2%) in City and Hackney were prescribed ICS.
By the final quarter of the 2-year post-intervention period,
prescribing rates in the mild-moderate COPD group fell to 26.9%
(n= 538/2003) in Tower Hamlets—a relative decrease of 23.0%.
The proportion of patients with mild-moderate COPD prescribed
ICS in City and Hackney fell to 29.9% (n= 489/1637) in the final
post-intervention quarter—a relative decrease of 9.9% (see Fig. 1).
ICS prescribing in the intervention CCG was stable during the
18-month pre-intervention period, with no significant change in
the proportion of people prescribed an ICS between each quarter
(β −0.06% per quarter, p= 0.701, linear regression). The propor-
tion of individuals prescribed an ICS declined significantly by
0.84% per quarter in the final 18 months post intervention (p <
0.001, linear regression). Regression analysis comparing the slope
of decline before and after the intervention showed that the rate
of decline accelerated significantly post intervention (p= 0.006,
linear regression) (see Table 1).
Prescribing rates in the intervention CCG (Tower Hamlets) were
significantly lower than in the comparison CCG (City and Hackney)
in the post-intervention period. Comparing prescribing in the final
18 months post intervention showed the average proportion of
individuals prescribed an ICS was 2.5% lower in the intervention
CCG (p < 0.003, linear regression).
Patients were classified as having stopped ICS if they were
prescribed an inhaler in one-quarter, but then not prescribed in
the three subsequent quarters. Using this definition, 23.6% (n=
219) of those with mild-moderate COPD in Tower Hamlets
stopped ICS, while 76.4% (n= 708) continued (see Table 2). Using
multivariable logistic regression adjusted for all predictors of
interest, deprivation score, and clustering by practice, we found
that South Asian ethnicity was associated increased odds of ICS
cessation (odds ratio (OR) South Asian vs. white 1.48, 95%
confidence interval (CI) 1.08–2.01, p= 0.013, logistic regression),
while having two or more comorbidities was associated with
Fig. 1 % Patient with mild-moderate COPD and no asthma prescribed ICS. ICS prescribing rates in Tower Hamlets (intervention CCG) and
City and Hackney (comparison CCG).
Table 1. ICS prescribing rates in Tower Hamlets (intervention CCG) and City and Hackney (comparison CCG).
Quarterly change in ICS
prescription
P value for quarterly change P value for difference in slopes pre- and
post intervention
Pre-intervention (Dec
2015–Mar 2017)
−0.06% 0.789 0.006
Post intervention (Apr
2017–Mar 2019)
−0.84% <0.001
% ICS in TH post intervention % ICS in CH post intervention Difference between CCGs, % p value
29.1 31.2 2.1, 0.022
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decreased odds of with ICS cessation (OR 2+ comorbidities vs.
none 0.27, 95% CI 0.14–0.51, p < 0.001, logistic regression). Age,
sex and baseline smoking status were not associated with ICS
cessation (see Table 3).
EMIS Web provides an estimated National Health Service (NHS)
cost for each medication extracted. The estimated annual cost of
ICS inhaler products decreased from £640,309 pre-intervention to
£532,732 post intervention—a reduction of 17%.
DISCUSSION
This study demonstrates that a programme providing clinical
guidance and education, IT support and financial incentivisation
to networks of GP practices is associated with a significant
acceleration in the reduction of ICS prescribing for those with
mild-moderate COPD.
The programme was innovative in that primary care clinicians,
rather than secondary care respiratory specialists, were enabled to
lead the withdrawal process. The evaluation demonstrates that
such a strategy is possible, provided that adequate community-
based clinical support from respiratory specialists is available if
required. Such programmes can also lead to substantial cost
savings.
The study used retrospective data from electronic health
records. The population of east London is comparatively mobile
and GP practices can see up to a quarter of their patients change
in 1 year. This was reflected in our data where significant numbers
of patients were not registered for at least one-quarter of the
study period. This may have underestimated the number of COPD
patients for each quarter, but it is not evident that they would be
more or less likely to be eligible for, or to engage with, an ICS
reduction programme.
Tower Hamlets has a history of introducing quality assurance to
spirometry performed in practice settings22. In the intervention
group, 99% of individuals had a recorded FEV1/FVC ratio.
However, 12% had a value falling above the obstructive threshold
of <0.7. Some of these patients, particularly those <60 years of
age, will have COPD with a FEV1/FVC ratio of >0.7, as the lower
limit of normal for FEV1/FVC varies with age23. There may have
been cases where spirometry results from hospital were not
transcribed into the GP record. Additionally, there may be some
diagnostic error in this routinely derived data set.
The local clinical guidance, which supported this programme,
encouraged clinicians to review eosinophil counts and exacerba-
tion rates; however, these criteria were not used to define the
cohort in the evaluation. Exacerbations and hospitalisations are
variably coded in the primary care record, meaning that including
these factors would reduce the reliability of the analysis.
No data were collected on clinical outcomes, which might
include adverse effects such as increased exacerbation rate or
reduced lung function following ICS reduction. The local clinical
guideline recommended regular clinical review during the
Table 2. Baseline characteristics of people who continue and stop
inhaled corticosteroids.
Non-stoppers Stoppers
N (%) N (%)
Denominator 708 219
Age at baseline (SD) 68.2 (11.8) 69.1 (12)
<60 years 169 (23.9) 47 (21.5)
≥60 years 539 (76.1) 172 (78.5)
Gender
Male 422 (59.6) 141 (64.4)
Female 286 (40.4) 78 (35.6)
Ethnic Group
White 513 (72.5) 142 (64.8)
South Asian 148 (20.9) 62 (28.3)
Black 18 (2.5) 7 (3.2)
Other/unknown 29 (4.1) 8 (3.7)
Deprivation quintile
1 (least deprived) 142 (20.1) 44 (20.2)
2 142 (20.1) 44 (20.2)
3 136 (19.2) 47 (21.6)
4 151 (21.4) 41 (18.8)
5 (most deprived) 136 (19.2) 42 (19.3)
Smoking Status
Current non-smoker 405 (57.7) 140 (64.2)
Current smoker 297 (42.3) 78 (35.8)
Baseline comorbidities
Atrial fibrillation 50 (7.1) 24 (11)
Cancer 70 (9.9) 22 (10)
CHD 146 (20.6) 54 (24.7)
CKD 131 (18.5) 44 (20.1)
Dementia 16 (2.3) 6 (2.7)
Depression 192 (27.1) 54 (24.7)
Diabetes 182 (25.7) 64 (29.2)
Epilepsy 13 (1.8) 4 (1.8)
Heart failure 42 (5.9) 25 (11.4)
Hypertension 341 (48.2) 106 (48.4)
Osteoporosis 46 (6.5) 12 (5.5)
Peripheral arterial disease 46 (6.5) 6 (2.7)
Rheumatoid arthritis 18 (2.5) 9 (4.1)
Serious mental illness 21 (3) 9 (4.1)
Stroke 48 (6.8) 16 (7.3)
aBaseline is date of first ICS prescription during post-intervention period.
Table 3. Odds of stopping inhaled corticosteroids.
Predictor Stoppers Non-stoppers OR (95%CI) p value
Age
<60 years (ref.) 169 (23.9) 47 (21.5) 1.00
≥60 years 539 (76.1) 172 (78.5) 1.11 (0.84,1.47) 0.474
Gender
Male (ref.) 422 (59.6) 141 (64.4) 1.00
Female 286 (40.4) 78 (35.6) 1.12 (0.84,1.51) 0.432
Ethnic group
White (ref.) 513 (72.5) 142 (64.8) 1.00
South Asian 148 (20.9) 62 (28.3) 1.48 (1.08,2.01) 0.013
Black 18 (2.5) 7 (3.2) 1.42 (0.70,2.85) 0.330
Other/unknown 29 (4.1) 8 (3.7) 1.04 (0.46,2.32) 0.932
Smoking status
Never/ex-
smoker (ref.)
405 (57.7) 140 (64.2) 0.80 (0.56,1.17) 0.252
Current smoker 297 (42.3) 78 (35.8) 0.84 (0.51,1.40) 0.507
Number of QOF comorbidities
0 491 (69.4) 140 (63.9) 0.92 (0.53,1.58) 0.759
1 180 (25.4) 63 (28.8) 1.01 (0.70,1.46) 0.943
2+ 37 (5.2) 16 (7.3) 0.27 (0.14,0.51) <0.001
aModel accounts for all factors reported in the table, and additionally,
clustering by practice and Townsend deprivation quintile.
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withdrawal phase, and provided advice in the event of clinical
deterioration. Clinicians were advised to restart ICS if appropriate
and seek advice from a respiratory physician.
Cost data for ICS products was based on 2019 prices.
Reductions in cost may have been due to the promotion of more
cost-effective brands of inhaler (particularly ICS/LABA combina-
tions) in addition to the reduction in volume of prescriptions
related to the ICS reduction programme.
The declining secular trend in ICS prescribing was reflected in
our study. Given the primary care-led approach of this ICS
reduction programme, the authors could find no similar studies
for comparison of effectiveness. RCT and real-world studies
provide data on patient adherence to ICS withdrawal; however,
it is not possible to infer from our data whether a patient did not
withdraw ICS because of the lack of appropriate clinical review,
patient dissent or attempted but abandoned withdrawal.
We found that ICS cessation was more successful in ethnic
minority groups, particularly patients of South Asian origin. Black
ethnicity was associated with a modest, but not statistically
significant increase in ICS cessation, possibly as a result of the
small numbers of patients in the study. This may be as a result of
health beliefs, which favour non-pharmacological intervention24.
Deprescribing was less successful in patients with greater
comorbidity, which may be attributable to the increasing
complexity of clinical encounters and number of healthcare
professionals involved25.
The development of managed practice networks in Tower
Hamlets since 2009 has been a key contextual factor in the
delivery and rapid implementation of quality improvement
programmes. Practice networks have the potential to improve
clinical performance through mechanisms of peer-to-peer support
and because financial incentives are directed at network, rather
than individual practice, performance22. The development of
primary care networks is a current NHS priority.
This evaluation demonstrates that a primary care-led pro-
gramme of ICS reduction is possible, well received by practice
clinicians and provides significant cost saving. This programme
could be replicated in primary care in other parts of the United
Kingdom, with significant potential benefits in terms of preventing
adverse effects of ICS therapy and improving the cost-
effectiveness of COPD management.
METHODS
Setting
East London is home to a young, ethnically diverse population
characterised by high levels of deprivation and multimorbidity. Smoking
prevalence and COPD admission rates are among the highest in London
(https://fingertips.phe.org.uk/profile/inhale). In Tower Hamlets, the inter-
vention clinical commissioning group (CCG), each practice is part of a
geographic network and receives additional funding through contracts for
enhanced services based on chronic disease indicators including COPD.
Intervention
A quality improvement programme to promote the stepwise withdrawal of
ICS was launched in the east London locality of Tower Hamlets in April
2017. The aim of the programme was to provide tools and support to GP
practice clinicians to undertake ICS withdrawal in primary care. All 35
practices, with a GP registered population of 347,054 in this CCG took part.
A neighbouring CCG, City and Hackney, acted as a natural control. All 76
GP practices in Tower Hamlets and City and Hackney use the EMIS Web
clinical system and hold information sharing agreements with the Clinical
Effectiveness Group (CEG), based at Queen Mary University of London. CEG
extract pseudonymised patient data to promote quality improvement
through evidence-based guidelines, standardised data entry templates and
clinical dashboards (https://www.qmul.ac.uk/blizard/ceg/).
The intervention components included:
(a) A brief clinical guideline developed through the CCG COPD working
group in collaboration with local stakeholders from primary care,
consultant respiratory physicians from the local hospital NHS trust
and the Tower Hamlets Public Health team. The guidance was based
on clinical evidence and programmes successfully undertaken
elsewhere21, and included an algorithm to support clinical decision
making (see Fig. 2) based on the risk assessment model from GOLD.
Patients with severe or very severe disease on spirometry (predicted
FEV1 < 50%), known or suspected asthma, eosinophilia, more than
one COPD exacerbation or any COPD admission in the past
12 months were excluded from the intervention. For patients
deemed potentially suitable for ICS withdrawal, the algorithm
prompted the clinician to consider inhaler technique, influenza
vaccination, smoking cessation and pulmonary rehabilitation as part
of clinical management. Regular clinical review was encouraged
throughout the ICS withdrawal period. The guidance provided
examples of stepwise reduction of ICS inhaler potency, along with
suggested actions if the patient experienced worsening breath-
lessness or increasing exacerbation frequency during withdrawal.
We developed an accompanying patient information leaflet,
which was piloted at a pulmonary rehabilitation group and
distributed to local practices (see Supplementary Fig. 2). The
programme was presented at CCG COPD study days, which were
attended by primary care clinicians from across the borough.
Quarterly multidisciplinary meetings were organised in each
network and were attended by primary care clinicians from each
practice and a Consultant Respiratory Physician from the local NHS
trust. These meetings provided primary care clinicians with
opportunities for education about COPD and the ICS withdrawal
programme, as well as a forum to discuss specific clinical cases.
(b) Practices were provided with two electronic tools within EMIS Web
to identify patients potentially eligible for ICS reduction: pop-up
consultation alerts to notify the clinician during a clinical contact
and searches to generate a list of patients for who COPD review may
be prioritised.
(c) Practices were financially incentivised to achieve a reduction of 20%
in ICS prescribing in the target group between April 2017 and March
2018. Incentives continued in the next financial year (2018–19)
based on a threshold target of ICS prescribing rather than a
reduction. This was to avoid penalising practices, which had already
made significant reductions. Practice performance against these
indicators compared to all other practices in the CCG was fed back
via monthly dashboards.
Data sources
Evaluation began 2 years into the programme in May 2019. Patient level
data were extracted for all individuals in Tower Hamlets and City and
Hackney with diagnosed COPD (as defined by the UK Quality and
Outcomes Framework (QOF) (https://digital.nhs.uk/data-and-information/
data-collections-and-data-sets/data-collections/quality-and-outcomes-
framework-qof) on a quarterly basis between December 2015 and April
2019. Individuals with a prior diagnosis of asthma were not included in the
study population.
Coded practice data relating to patient demographics, disease
characteristics (smoking status, diagnostic FEV1/FVC ratio, and latest
predicted FEV1%), QOF comorbidities (Atrial Fibrillation, Cancer, Coronary
Heart Disease, Chronic Kidney Disease, Dementia, Depression, Diabetes,
Epilepsy, Heart Failure, Hypertension, Osteoporosis, Peripheral Arterial
Disease, Rheumatoid Arthritis, Serious Mental Illness and Stroke) and ICS
prescribing were extracted for the six quarters before and eight quarters
after the intervention (see Supplementary Table 1). All data were de-
identified and managed according to the UK NHS information governance
requirements. Ethical approval was not required for this report as it relies
on the use of routinely recorded de-identified data published in aggregate
form. All GPs in the participating east London practices consented to the
use of their anonymised patient data for research and development for
patient benefit.
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Statistical analysis
An interrupted time-series analysis examined the proportion of individuals
with mild-moderate COPD (defined as their latest FEV1 > 50%) prescribed
an ICS in each quarter of the study period. Linear regression was employed
to compare the quarterly change in prescribing for the pre-intervention
period (Q3 financial year 2015–2016—Q4 financial year 2016–2017) to that
in the post-intervention period (Q1 financial year 2017–2018—Q4 financial
year 2018–2019).
Within the intervention CCG of Tower Hamlets, a nested case–control
study was conducted to identify predictors of ICS cessation. Individuals
with mild-moderate COPD prescribed an ICS at any point during follow-up
were eligible for inclusion. Cases were defined as individuals who had
ceased ICS for at least 9 months (three quarters) following a first ICS
prescription in the study period. Controls were defined as individuals who
were prescribed an additional ICS at any point over the 9 months following
their index prescription. Demographic and comorbidity data were
collected at the time of first ICS prescription. Individuals with <9 months
of follow-up were excluded from the study; reasons for this included de-
registering from their GP practice during the study period, or having their
first ICS prescription <9 months before the end of the follow-up period.
Multivariable logistic regression analysis was used to identify predictors
of ICS cessation. Predictors of interest included age, gender, ethnicity,
smoking status, comorbidity (measured as count of QOF conditions at the
time of first ICS prescription). The models additionally adjusted for
Townsend deprivation quintile and clustering by practice. All analyses
were completed using Stata version 15.
Reporting summary
Further information on research design is available in the Nature Research
Reporting Summary linked to this article.
Fig. 2 Algorithm to support primary care clinicians make clinical management decisions relating to ICS therapy. Patient identification and
management of ICS Withdrawal Algorithm provided to clinicians within local clinical guideline.
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